Erasca Stock Soars to New High on Analyst Optimism
Erasca Inc. shares surged 15% to a three-year high after four investment firms issued bullish ratings and raised price targets, citing positive clinical trial data.
Topic
Latest reporting and analysis tagged with Analyst Ratings.
Erasca Inc. shares surged 15% to a three-year high after four investment firms issued bullish ratings and raised price targets, citing positive clinical trial data.
Sally Beauty Holdings stock has risen more than 53% in the past six months. Analysts from TD Cowen and Canaccord Genuity maintain Buy ratings, citing strategic initiatives like Sally Ignited and digital investments. The company's fiscal Q1 2026 earnings are expected on January 29, 2026.
Terns Pharmaceuticals saw analyst support with Truist and Mizuho reiterating buy ratings after Phase 1 data for its CML drug TERN-701 showed a 64% response rate, with shares up over 300% in three months.
Truist initiated coverage of Palantir with a Buy rating and $223 target, citing AI-driven growth, while RBC Capital reiterated a Sell rating with a $50 target.
Fortinet received updated ratings from RBC Capital and Piper Sandler on January 5, with price targets adjusted. The company will announce its fiscal Q4 and full-year 2025 results on February 5.
Pfizer announced positive results from a BREAKWATER trial cohort for BRAFTOVI in metastatic colorectal cancer, showing a 64% response rate. The company also received recent analyst ratings.
Barclays raised Vale's price target to $15.50 on January 8, while Scotiabank downgraded it to Sector Perform. Wells Fargo increased its target to $13 in December, citing supply constraints.
Banco Santander received several analyst rating updates in January and announced a new U.S. equity research alliance in December.